Work With Data
Profile
user

Rhinomed

Updated: 3d ago
bookmarkBookmark

Rhinomed is a company. It is a private company in Cremorne, Australia. It was founded in 2013 and its current CEO is Michael Johnson. It is part of the Health Care sector, specifically in the Health Care Equipment & Supplies industry.

Key facts

plus See more facts

Extract data

Download datasets about Rhinomed:

dataset Dataset of stocks from Rhinomed:

Rhinomed is one of the companies in Australia, companies in Health Care Equipment & Supplies, companies in Health Care, companies in Cremorne and 3,456,808 companies in our database.

Talking Points

  • Rhinomed - Wearable Nasal Technology
  • Rhinomed is a global medical device company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery.
  • Rhinomed is an ASX listed (RNO:AU) Melbourne Australia based medical technology firm that has developed a patented nasal and respiratory technology platform capable...
  • Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

Related

Connected or similar to Rhinomed: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.